

IN THE CLAIMS:

Please amend claim 38 to read as follows. All claims pending, including those unchanged by the present amendment, are reproduced below for the convenience of the Examiner.

- 1 1. (Original) A method for delivery of a compound to the surface of, into or
2 across a biological barrier, the method comprising contacting the barrier with a composition
3 comprising the compound and a delivery-enhancing transporter,
4 wherein the delivery-enhancing transporter comprises sufficient guanidino
5 or amidino moieties to increase delivery of the compound into or across the barrier compared to
6 delivery of the compound in the absence of the delivery-enhancing transporter.

- 1 2. (Original) The method of claim 1, wherein the delivery-enhancing
2 transporter comprises a peptide backbone.

- 1 3. (Original) The method of claim 1, wherein the delivery-enhancing
2 transporter comprises a non-peptide backbone.

- 1 4. (Original) The method of claim 1, wherein the delivery-enhancing
2 transporter comprises from 6 to 50 guanidino or amidino moieties.

- 1 5. (Original) The method of claim 4, wherein the delivery-enhancing
2 transporter comprises from 7 to 15 guanidino moieties.

- 1 6. (Original) The method of claim 1, wherein the delivery-enhancing
2 transporter comprises at least 6 contiguous subunits which each include a guanidino or amidino
3 moiety.

1 **7.** (Original) The method of claim 1, wherein the delivery-enhancing
2 transporter comprises from 6 to 50 subunits, at least 50% of which include a guanidino or
3 amidino moiety.

1 **8.** (Original) The method of claim 7, wherein at least about 70% of the
2 subunits in the delivery-enhancing transporter include a guanidino moiety.

1 **9.** (Original) The method of claim 7, wherein each subunit includes a
2 guanidino moiety.

1 **10.** (Original) The method of claim 7, wherein the subunits are selected from
2 the group consisting of L-arginine, D-arginine, L-homoarginine and D-homoarginine residues.

1 **11.** (Original) The method of claim 10, wherein each subunit is independently a
2 D- or L-arginine residue.

1 **12.** (Original) The method of claim 11, wherein at least one subunit is D-
2 arginine.

1 **13.** (Original) The method of claim 12, wherein all of the arginine residues
2 have a D-configuration.

1 **14.** (Original) The method of claim 1, wherein the compound is a modified
2 biological agent.

1 **15.** (Original) The method of claim 1, wherein the composition comprises at
2 least two delivery-enhancing transporters.

1 **16.** (Original) The method of claim 1, wherein the barrier is an intact epithelial
2 or endothelial tissue layer or layers.

1 **17.** (Original) The method of claim 1, wherein the compound is a diagnostic
2 imaging or contrast agent.

1 **18.** (Original) The method of claim 1, wherein the compound is a non-nucleic
2 acid.

1 **19.** (Original) The method of claim 1, wherein the compound is a non-
2 polypeptide.

1 **20.** (Original) The method of claim 1, wherein the compound is selected from
2 the group consisting of antibacterials, antifungals, antivirals, antiproliferatives,
3 immunosuppressives, vitamins, analgesics, and hormones.

1 **21.** (Original) The method of claim 1, wherein the biological barrier is skin.

1 **22.** (Original) The method of claim 21, wherein the compound is delivered into
2 and across one or more of the stratum corneum, stratum granulosum, stratum lucidum and
3 stratum germinativum.

1 **23.** (Original) The method of claim 21, wherein the compound crosses the
2 stratum corneum in the absence of skin pretreatment.

1 **24.** (Original) The method of claim 21, wherein the composition is
2 administered topically and the compound is taken up by cells that comprise the follicular or
3 interfollicular epidermis.

1 **25.** (Original) The method of claim **21**, wherein the composition is
2 administered by a transdermal patch.

1 **26.** (Original) The method of claim **1**, wherein the compound is a therapeutic
2 agent for a condition selected from the group consisting of Crohn's disease, ulcerative colitis,
3 gastrointestinal ulcers, peptic ulcer disease, and abnormal proliferative diseases.

1 **27.** (Original) The method of claim **26**, wherein the compound is a therapeutic
2 for ulcers and is selected from the group consisting of an H₂ histamine inhibitor, an inhibitor of
3 the proton-potassium ATPase, and an antibiotic directed at *Helicobacter pylori*.

1 **28.** (Original) The method of claim **1**, wherein the compound is a therapeutic
2 agent for treating a bronchial condition selected from the group consisting of cystic fibrosis,
3 asthma, allergic rhinitis, and chronic obstructive pulmonary disease.

1 **29.** (Original) The method of claim **1**, wherein the therapeutic agent is an
2 antiinflammatory agent selected from the group consisting of a corticosteroid, cromolyn, and
3 nedocromil.

1 **30.** (Original) The method of claim **1**, wherein the compound is a therapeutic
2 agent for treating ischemia, Parkinson's disease, schizophrenia, cancer, acquired immune
3 deficiency syndrome (AIDS), infections of the central nervous system, epilepsy, multiple
4 sclerosis, neurodegenerative disease, trauma, depression, Alzheimer's disease, migraine, pain,
5 and a seizure disorder.

1 **31.** (Original) The method of claim **1**, wherein the compound is selected from
2 the group consisting of cyclosporin, insulin, a vasopressin, a leucine enkephalin, calcitonin, 5-
3 fluorouracil, a salicylamide, a β-lactone, an ampicillin, a penicillin, a cephalosporin, a β-

4 lactamase inhibitor, a quinolone, a tetracycline, a macrolide, a gentamicin, acyclovir, ganciclovir,
5 a trifluoropyridine, and pentamidine.

1 **32.** (Original) A composition comprising:
2 an effective amount of a biologically active agent;
3 a delivery-enhancing transporter having sufficient guanidino or amidino moieties to
4 increase delivery of the biologically active agent across a biological barrier
5 compared to the delivery of the biologically active agent in the absence of the
6 transporter; and
7 a pharmaceutically acceptable carrier.

1 **33.** (Original) The composition of claim 32, wherein the biologically active
2 agent is selected from the group consisting of antiviral agents, antibacterial agents, antifungal
3 agents, antiproliferative agents, immunosuppressive agents, vitamins, analgesic agents and
4 hormones.

1 **34.** (Original) The composition of claim 33, wherein the biologically active
2 agent is an antiviral agent selected from the group consisting of acyclovir, famciclovir,
3 ganciclovir, foscarnet, idoxuridine, sorivudine, trifluridine, valacyclovir, cidofovir, didanosine,
4 stavudine, zalcitabine, zidovudine, ribavirin and rimantatine.

1 **35.** (Original) The composition of claim 32, wherein the biologically active
2 agent is an antibacterial agent selected from the group consisting of nafcillin, oxacillin,
3 penicillin, amoxacillin, ampicillin, cefotaxime, ceftriaxone, rifampin, minocycline, ciprofloxacin,
4 norfloxacin, erythromycin and vancomycin.

1 **36.** (Original) The composition of claim 32, wherein the biologically active
2 agent is an antifungal agent selected from the group consisting of amphotericin, itraconazole,

3 ketoconazole, miconazole, nystatin, clotrimazole, fluconazole, ciclopirox, econazole, naftifine,
4 terbinafine and griseofulvin.

1 **37.** (Original) The composition of claim 32, wherein the biologically active
2 agent is an antineoplastic agent selected from the group consisting of pentostatin, 6-
3 mercaptopurine, 6-thioguanine, methotrexate, bleomycins, etoposide, teniposide, dactinomycin,
4 daunorubicin, doxorubicin, mitoxantrone, hydroxyurea, 5-fluorouracil, cytarabine, fludarabine,
5 mitomycin, cisplatin, procarbazine, dacarbazine, paclitaxel, colchicine, and the vinca alkaloids.

1 **38.** (Currently amended) The composition of claim 32, wherein the biologically
2 active agent is an immunosuppressive agent selected from the group consisting of methotrexate,
3 azathioprine, fluorouracil, hydroxyurea, 6-thioguanine, chclophosphamide, mechloroethamine
4 hydrochloride, carmustine, cyclosporine, taxol or a phosphate-cleavable taxol conjugate,
5 tacrolimus, vinblastine, dapsone and sulfasalazine.

1 **39.** (Original) The composition of claim 32, wherein the biologically active
2 agent is an analgesic agent selected from the group consisting of lidocaine, bupivacaine,
3 novocaine, procaine, tetracaine, benzocaine, cocaine, mepivacaine, etidocaine, proparacaine
4 ropivacaine and prilocaine.

1 **40.** (Original) The composition of claim 33, wherein the delivery enhancing
2 transporter is a peptide having from about 6 to about 15 amino acids residues wherein from 6 to
3 about 12 residues are selected from the group consisting of L-arginine, D-arginine, L-
4 homoarginine and D-homoarginine.